CY1114243T1

Patents

Full documents

Title

Abstract

Claims

All

Any

Exact

Not

Add AND condition

These CPCs and their children

These exact CPCs

Add AND condition

Exact

Exact Batch

Similar

Substructure

Substructure (SMARTS)

Full documents

Claims only

Add AND condition

Application Numbers

Publication Numbers

Either

Add AND condition

Συνθεσεις εμβολιου κατα της ναϊσσερια, που περιεχουν εναν συνδυασμο αντιγονων

Abstract

Η παρούσα εφεύρεση αφορά ανοσογόνες συνθέσεις και εμβόλια για την αντιμετώπιση και την πρόληψη της νόσου της Ναϊσσέρια. Οι ανοσογόνες συνθέσεις της εφεύρεσης περιέχουν συνδυασμούς αντιγόνων, τα οποία επιλέγονται από τουλάχιστον δύο διαφορετικές τάξεις αντιγόνων, που περιλαμβάνουν τις προσκολλητίνες, πρωτεΐνες αυτομεταφορέα, τοξίνες, σιδηροδεσμευτικές πρωτεΐνες και μεμβρανικές πρωτεΐνες (κατά προτίμηση ολοκληρωμένες πρωτεΐνες εξωτερικής μεμβράνης). Τέτοιοι συνδυασμοί αντιγόνων είναι σε θέση να στοχεύσουν την ανοσοαπόκριση έναντι διαφορετικών πλευρών του κύκλου ζωής της Ναϊσσέρια, με αποτέλεσμα μια πιο αποτελεσματική ανοσοαπόκριση.

Classifications

A61K39/095

Neisseria

View 19 more classifications

Landscapes

Health & Medical Sciences

Life Sciences & Earth Sciences

CY1114243T1

Cyprus

Find Prior Art

Similar

Other languages: English
Inventor: Francois-Xavier Jacques Berthet; Ralph Biemans; Philippe Denoel; Christiane Feron; Carine Goraj; Jan Poolman; Vincent Weynants

2003

2004

2005

2008

2010

2011

2012

2013

2015

2016

First worldwide family litigation filed

2013-05-31

Application filed by Glaxosmithkline Biologicals S.A.

2015-12-09

Publication of CY1114243T1

Show all events

Info: Patent citations (131); Cited by (139); Similar documents; Priority and Related Applications
External links: Espacenet; Global Dossier; Discuss

Patent Citations (131)

Publication number Priority date Publication date Assignee Title

Family To Family Citations

US4239746A

* 1973-06-30 1980-12-16 Dezso Istvan Bartos Complement fixation test employing reactants in a disposable package

DE2744721A1

1977-10-05 1979-04-19 Veba Chemie Ag Pulverfoermige ueberzugsmittel und deren anwendung

DE2848965A1

1978-11-11 1980-05-22 Behringwerke Ag Verfahren zur herstellung von membranproteinen aus neisseria meningitidis und diese enthaltende vaccine

EP0027888B1

1979-09-21 1986-04-16 Hitachi, Ltd. Semiconductor switch

US4271147A

1980-01-10 1981-06-02 Behringwerke Aktiengesellschaft Process for the isolation of membrane proteins from Neisseria meningitidis and vaccines containing same

US4673574A

1981-08-31 1987-06-16 Anderson Porter W Immunogenic conjugates

US4695624A

1984-05-10 1987-09-22 Merck & Co., Inc. Covalently-modified polyanionic bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers, and methods of preparing such polysaccharides and conjugates and of confirming covalency

US20020146764A1

* 1985-03-28 2002-10-10 Chiron Corporation Expression using fused genes providing for protein product

IT1187753B

1985-07-05 1987-12-23 Sclavo Spa Coniugati glicoproteici ad attivita' immunogenica trivalente

DE3622221A1

* 1986-07-02 1988-01-14 Max Planck Gesellschaft Verfahren zur gentechnologischen gewinnung von proteinen unter verwendung gramnegativer wirtszellen

US5173294A

1986-11-18 1992-12-22 Research Foundation Of State University Of New York Dna probe for the identification of haemophilus influenzae

RU2023448C1

1987-07-30 1994-11-30 Сентро Насьональ Де Биопрепарадос Способ получения вакцины против различных патогенных серотипов менингита нейссера группы в

HUT58804A

1988-12-16 1992-03-30 James Cleland Paton Process for producing pneumolysine mutants and pneumococcus vaccines

US7118757B1

* 1988-12-19 2006-10-10 Wyeth Holdings Corporation Meningococcal class 1 outer-membrane protein vaccine

CU22302A1

* 1990-09-07 1995-01-31 Cigb Secuencia nucleotidica codificante para una proteina de la membrana externa de neisseria meningitidis y uso de dicha proteina en preparados vacunales

ATE242784T1

1990-07-16 2003-06-15 Univ North Carolina Mit der familie der hämolysin-toxine verwandte antigene eisen-ubnterdrückende proteine des n. meningitis

DE4023721A1

1990-07-26 1992-01-30 Boehringer Mannheim Gmbh Verfahren zur herstellung von vakzinen und ihre verwendung

US5912336A

1990-08-23 1999-06-15 University Of North Carolina At Chapel Hill Isolated nucleic acid molecules encoding transferrin binding proteins from Neisseria gonorrhoeae and Neisseria meningitidis

DE69133334T2

1990-08-23 2004-05-13 University Of North Carolina At Chapel Hill Transferrin bindende proteine aus neisseria-gonorrhoeae und neisseria-meningitidis

US5153312A

1990-09-28 1992-10-06 American Cyanamid Company Oligosaccharide conjugate vaccines

US5652211A

1991-02-11 1997-07-29 Biosynth S.R.L. Peptides for neutralizing the toxicity of Lipid A

US5371186A

1991-02-11 1994-12-06 Biosynth S.R.L. Synthetic peptides for detoxification of bacterial endotoxins and for the prevention and treatment of septic shock

US5476929A

1991-02-15 1995-12-19 Uab Research Foundation Structural gene of pneumococcal protein

US6592876B1

1993-04-20 2003-07-15 Uab Research Foundation Pneumococcal genes, portions thereof, expression products therefrom, and uses of such genes, portions and products

EP0575553B1

* 1991-03-14 1998-12-16 Imclone Systems, Inc. Recombinant hybrid porin epitopes

US5552146A

1991-08-15 1996-09-03 Board Of Regents, The University Of Texas System Methods and compositions relating to useful antigens of Moraxella catarrhalis

FR2682041B1

1991-10-03 1994-01-14 Pasteur Merieux Serums Vaccins Vaccin contre les infections a neisseria meningitidis.

WO1993014155A1

1992-01-13 1993-07-22 Akzo Nobel N.V. Crosslinking of rubbers with engineering plastics

JP3917172B2

1992-02-11 2007-05-23 ヘンリーエム．ジャクソンファウンデーションフォーザアドバンスメントオブミリタリーメディスン二重担体の免疫原性構成体

FR2692592B1

1992-06-19 1995-03-31 Pasteur Merieux Serums Vacc Fragments d'ADN codant pour les sous-unités du récepteur de la transferrine de Neisseria meningitidis et procédés les exprimant.

DK0671948T3

1992-06-25 1997-09-01 Smithkline Beecham Biolog Vaccinepræparat indeholdende adjuvanser

NL9201716A

1992-10-02 1994-05-02 Nederlanden Staat Buitenmembraanvesikel dat voorzien is van een groep polypeptiden welke ten minste de immuunwerking van aan membraan gebonden buitenmembraaneiwitten (OMP's) hebben, werkwijze ter bereiding ervan alsmede een vaccin dat een dergelijk buitenmembraanvesikel omvat.

GB9224584D0

1992-11-23 1993-01-13 Connaught Lab Use of outer membrane protein d15 and its peptides as vaccine against haempohilus influenzae diseases

WO1994026304A1

1993-05-18 1994-11-24 Ohio State Research Foundation Otitis media vaccine

US5439808A

* 1993-07-23 1995-08-08 North American Vaccine, Inc. Method for the high level expression, purification and refolding of the outer membrane group B porin proteins from Neisseria meningitidis

US6361779B1

1993-11-08 2002-03-26 Aventis Pasteur Limited Transferrin receptor genes

DK0728200T3

1993-11-08 2007-01-08 Sanofi Pasteur Ltd Haemophilus-transferrin-receptorgener

GB9326253D0

1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines

EP1167377B2

1994-07-15 2012-08-08 University of Iowa Research Foundation Immunomodulatory oligonucleotides

US5565204A

1994-08-24 1996-10-15 American Cyanamid Company Pneumococcal polysaccharide-recombinant pneumolysin conjugate vaccines for immunization against pneumococcal infections

US5545553A

1994-09-26 1996-08-13 The Rockefeller University Glycosyltransferases for biosynthesis of oligosaccharides, and genes encoding them

IL117483A

1995-03-17 2008-03-20 Bernard Brodeur MENINGITIDIS NEISSERIA shell protein is resistant to proteinase K.

US6287574B1

* 1995-03-17 2001-09-11 Biochem Pharma Inc. Proteinase K resistant surface protein of neisseria meningitidis

US6265567B1

1995-04-07 2001-07-24 University Of North Carolina At Chapel Hill Isolated FrpB nucleic acid molecule

UA56132C2

1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини

US6440425B1

1995-05-01 2002-08-27 Aventis Pasteur Limited High molecular weight major outer membrane protein of moraxella

US5843464A

1995-06-02 1998-12-01 The Ohio State University Synthetic chimeric fimbrin peptides

US6007838A

1995-06-07 1999-12-28 The United States Of America As Represented By The Secretary Of The Army Process for making liposome preparation

EA199800046A1

1995-06-07 1998-06-25 Байокем Вэксинс Инк. Полипептид, последовательность днк, вакцинная композиция (варианты), антитело или его фрагмент, вакцина, применения указанных полипептида, последовательности днк и антитела или его фрагмента

GB9513074D0

1995-06-27 1995-08-30 Cortecs Ltd Novel anigen

US6476201B1

* 1995-09-18 2002-11-05 Id Biomedical Corporation Of Quebec Methods for the production of non-covalently complexed and multivalent proteosome sub-unit vaccines

US6290970B1

1995-10-11 2001-09-18 Aventis Pasteur Limited Transferrin receptor protein of Moraxella

US6440701B1

1996-03-08 2002-08-27 Aventis Pasteur Limited Transferrin receptor genes of Moraxella

US6090576A

1996-03-08 2000-07-18 Connaught Laboratories Limited DNA encoding a transferrin receptor of Moraxella

JP2000511411A

1996-05-01 2000-09-05 ザロックフェラーユニヴァーシティ抗―肺炎球菌ワクチン用のコリン結合タンパク質

US7341727B1

1996-05-03 2008-03-11 Emergent Product Development Gaithersburg Inc. M. catarrhalis outer membrane protein-106 polypeptide, methods of eliciting an immune response comprising same

FR2751000B1

1996-07-12 1998-10-30 Inst Nat Sante Rech Med Adn specifiques des bacteries de l'espece neisseria meningitidis, leurs procedes d'obtention et leurs applications biologiques

US5882896A

1996-09-24 1999-03-16 Smithkline Beecham Corporation M protein

US5882871A

1996-09-24 1999-03-16 Smithkline Beecham Corporation Saliva binding protein

AU5194598A

1996-10-31 1998-05-22 Human Genome Sciences, Inc. (streptococcus pneumoniae) antigens and vaccines

JP2001502925A

1997-06-03 2001-03-06 コノートラボラトリーズリミテッドモラクセラのラクトフェリン受容体遺伝子

HUP0002475A3

1997-07-21 2002-01-28 Baxter Healthcare S A Wallisel Modified immunogenic pneumolysin compositions as vaccines

AU4773697A

1997-07-31 1999-02-22 Wilo Gmbh Latent heat storage device for use in a vehicle

EP1003874B1

1997-08-15 2006-11-02 Rijksuniversiteit Utrecht Neisseria lactoferrin binding protein

GB9717953D0

1997-08-22 1997-10-29 Smithkline Beecham Biolog Vaccine

US6914131B1

* 1998-10-09 2005-07-05 Chiron S.R.L. Neisserial antigens

GB9726398D0

* 1997-12-12 1998-02-11 Isis Innovation Polypeptide and coding sequences

CA2317815A1

* 1998-01-14 1999-07-22 Chiron S.P.A. Neisseria meningitidis antigens

CA2264970A1

* 1998-03-10 1999-09-10 American Cyanamid Company Antigenic conjugates of conserved lipolysaccharides of gram negative bacteria

ATE461709T1

1998-04-07 2010-04-15 Medimmune Llc Choline-bindende proteine derivate aus pneumokoken als impfstoff

GB9808734D0

1998-04-23 1998-06-24 Smithkline Beecham Biolog Novel compounds

GB9808866D0

* 1998-04-24 1998-06-24 Smithkline Beecham Biolog Novel compounds

PT1093517E

* 1998-05-01 2008-06-12 Novartis Vaccines & Diagnostic Antigénios e composições da neisseria msningitidis

US20070026021A1

* 1998-05-01 2007-02-01 Chiron S.R.I. Neisseria meningitidis antigens and compositions

GB9809683D0

1998-05-06 1998-07-01 Smithkline Beecham Biolog Novel compounds

GB9810276D0

1998-05-13 1998-07-15 Smithkline Beecham Biolog Novel compounds

GB9810285D0

1998-05-13 1998-07-15 Smithkline Beecham Biolog Novel compounds

GB9811260D0

1998-05-26 1998-07-22 Smithkline Beecham Biolog Novel compounds

US6248329B1

* 1998-06-01 2001-06-19 Ramaswamy Chandrashekar Parasitic helminth cuticlin nucleic acid molecules and uses thereof

KR100911277B1

1998-06-03 2009-08-11 글락소스미스클라인 바이오로지칼즈 에스.에이. 모락셀라 카탈리스로부터의 ｂａｓｂ027 단백질 및 유전자,항원, 항체, 및 이들의 용도

GB9812163D0

1998-06-05 1998-08-05 Smithkline Beecham Biolog Novel compounds

GB9812440D0

1998-06-09 1998-08-05 Smithkline Beecham Biolog Novel compounds

GB9814902D0

1998-07-10 1998-09-09 Univ Nottingham Screening of neisserial vaccine candidates against pathogenic neisseria

US6951652B2

1998-07-29 2005-10-04 Biosynth S.R.L. Vaccine for prevention of gram-negative bacterial infections and endotoxin related diseases

GB9818004D0

* 1998-08-18 1998-10-14 Smithkline Beecham Biolog Novel compounds

GB9820003D0

1998-09-14 1998-11-04 Smithkline Beecham Biolog Novel compounds

GB9820002D0

1998-09-14 1998-11-04 Smithkline Beecham Biolog Novel compounds

MXPA01003557A

* 1998-10-09 2004-04-05 Chiron Corp Secuencias genomicas de neisseria y metodos para su uso.

ES2246093T3

1998-10-16 2006-02-01 Fraunhofer-Gesellschaft Zur Forderung Der Angewandten Forschung E.V. Patogenicida molecular que induce una resistencia a la enfermedad en las plantas.

CA2347849C

1998-10-22 2013-06-25 The University Of Montana Omp85 proteins of neisseria gonorrhoeae and neisseria meningitidis, compositions containing same and methods of use thereof

US6610306B2

* 1998-10-22 2003-08-26 The University Of Montana OMP85 protein of neisseria meningitidis, compositions containing the same and methods of use thereof

GB9823978D0

1998-11-02 1998-12-30 Microbiological Res Authority Multicomponent meningococcal vaccine

US20030215469A1

* 1998-11-02 2003-11-20 Microbiological Research Authority Multicomponent meningococcal vaccine

EP1127137B2

1998-11-03 2013-12-25 De Staat Der Nederlanden Vertegenwoordigd Door De Minister Van Welzijn, Volksgezondheid En Cultuur Lps with reduced toxicity from genetically modified gram negative bacteria

NZ530640A

* 1999-04-30 2006-06-30 Chiron S Conserved neisserial antigens

CA2371032A1

* 1999-04-30 2000-11-09 Chiron Corporation Neisseria genomic sequences and methods of their use

WO2000071725A2

* 1999-05-19 2000-11-30 Chiron S.P.A. Combination neisserial compositions

GB9911683D0

* 1999-05-19 1999-07-21 Chiron Spa Antigenic peptides

EP1218512A2

1999-06-18 2002-07-03 Elitra Pharmaceuticals, Inc. Nucleotide sequences of moraxella catarrhalis genome

GB2351515B

1999-06-29 2002-09-11 Pandrol Ltd Adjustable railway rail fastening assembly and methods for use therewith

GB9917977D0

1999-07-30 1999-09-29 Smithkline Beecham Biolog Novel compounds

GB9918038D0

1999-07-30 1999-09-29 Smithkline Beecham Biolog Novel compounds

GB9918208D0

1999-08-03 1999-10-06 Smithkline Beecham Biolog Novel compounds

GB9918302D0

1999-08-03 1999-10-06 Smithkline Beecham Biolog Novel compounds

GB9918319D0

* 1999-08-03 1999-10-06 Smithkline Beecham Biolog Vaccine composition

US6531131B1

* 1999-08-10 2003-03-11 The United States Of America As Represented By The Department Of Health And Human Services Conjugate vaccine for Neisseria meningitidis

AUPQ275799A0

* 1999-09-10 1999-10-07 Luminis Pty Limited Recombinant bacterium expressing an oligosaccharide receptor mimic

JP4840956B2

1999-11-29 2011-12-21 ノバルティスヴァクシンズアンドダイアグノスティクスエスアールエル８５ｋＤａのナイセリア抗原

EP2281570A3

* 2000-01-17 2012-05-09 Novartis Vaccines and Diagnostics S.r.l. Outer membrane vesicle (OMV) vaccine comprising n. meningitidis serogroup B outer membrane proteins

CA2398139A1

2000-01-25 2001-08-02 The University Of Queensland Proteins comprising conserved regions of neisseria meningitidis surface antigen nhha

PT2270030E

2000-02-28 2012-07-24 Novartis Vaccines & Diagnostic Expressão heteróloga de proteínas de neisseria

GB0007432D0

* 2000-03-27 2000-05-17 Microbiological Res Authority Proteins for use as carriers in conjugate vaccines

GB0011108D0

* 2000-05-08 2000-06-28 Microscience Ltd Virulence gene and protein and their use

KR20030024811A

2000-07-27 2003-03-26 칠드런즈 하스피틀 앤드 리써치 센터 앳 오클랜드 나이세리아 메닌지티디스에 의하여 유발되는 질병에 대한광범위하게 유효한 보호를 위한 백신

GB0103424D0

* 2001-02-12 2001-03-28 Chiron Spa Gonococcus proteins

GB0108024D0

* 2001-03-30 2001-05-23 Chiron Spa Bacterial toxins

GB0115176D0

* 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines

GB0118249D0

* 2001-07-26 2001-09-19 Chiron Spa Histidine vaccines

WO2003009869A1

2001-07-26 2003-02-06 Chiron Srl. Vaccines comprising aluminium adjuvants and histidine

GB0121591D0

* 2001-09-06 2001-10-24 Chiron Spa Hybrid and tandem expression of neisserial proteins

ES2615362T3

* 2001-07-27 2017-06-06 Glaxosmithkline Biologicals Sa Adhesinas de meningococos

CA2462646C

2001-10-03 2013-02-12 Chiron Corporation Adjuvanted meningococcus compositions

EP1524990A2

* 2002-08-02 2005-04-27 GlaxoSmithKline Biologicals S.A. Vaccine composition comprising lipooligosaccharide with reduced phase variability

CA2501812C

* 2002-10-11 2012-07-10 Mariagrazia Pizza Polypeptide-vaccines for broad protection against hypervirulent meningococcal lineages

US10272147B2

* 2003-01-30 2019-04-30 Glaxosmithkline Biologicals S.A. Injectable vaccines against multiple meningococcal serogroups

GB0315021D0

* 2003-06-26 2003-07-30 Chiron Srl Immunogenic gonococcal compositions

GB0323103D0

* 2003-10-02 2003-11-05 Chiron Srl De-acetylated saccharides

SI1961426T1

* 2003-10-02 2011-10-28 Novartis Ag Kombinirana cepiva proti meningitisu

GB0408977D0

* 2004-04-22 2004-05-26 Chiron Srl Immunising against meningococcal serogroup Y using proteins

GB0409748D0

* 2004-04-30 2004-06-09 Chiron Srl Lactoferrin cleavage

CA2656474A1

* 2006-06-29 2008-01-03 Novartis Ag Polypeptides from neisseria meningitidis

* Cited by examiner, † Cited by third party

Cited By (139)

Publication number Priority date Publication date Assignee Title

Family To Family Citations

PT1093517E

1998-05-01 2008-06-12 Novartis Vaccines & Diagnostic Antigénios e composições da neisseria msningitidis

US10967045B2

* 1998-11-02 2021-04-06 Secretary of State for Health and Social Care Multicomponent meningococcal vaccine

GB9823978D0

* 1998-11-02 1998-12-30 Microbiological Res Authority Multicomponent meningococcal vaccine

NZ530640A

1999-04-30 2006-06-30 Chiron S Conserved neisserial antigens

WO2000071725A2

1999-05-19 2000-11-30 Chiron S.P.A. Combination neisserial compositions

GB9918319D0

* 1999-08-03 1999-10-06 Smithkline Beecham Biolog Vaccine composition

ES2539951T3

1999-10-29 2015-07-07 Novartis Vaccines And Diagnositics S.R.L. Péptidos antigénicos de Neisseria

GB9928196D0

1999-11-29 2000-01-26 Chiron Spa Combinations of B, C and other antigens

CA2398139A1

* 2000-01-25 2001-08-02 The University Of Queensland Proteins comprising conserved regions of neisseria meningitidis surface antigen nhha

PT2270030E

* 2000-02-28 2012-07-24 Novartis Vaccines & Diagnostic Expressão heteróloga de proteínas de neisseria

KR20030024811A

GB0118249D0

2001-07-26 2001-09-19 Chiron Spa Histidine vaccines

GB0121591D0

2001-09-06 2001-10-24 Chiron Spa Hybrid and tandem expression of neisserial proteins

ES2615362T3

2001-07-27 2017-06-06 Glaxosmithkline Biologicals Sa Adhesinas de meningococos

US7214660B2

2001-10-10 2007-05-08 Neose Technologies, Inc. Erythropoietin: remodeling and glycoconjugation of erythropoietin

US7173003B2

2001-10-10 2007-02-06 Neose Technologies, Inc. Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF

EP1524990A2

GB0220194D0

* 2002-08-30 2002-10-09 Chiron Spa Improved vesicles

CA2501812C

GB0227346D0

2002-11-22 2002-12-31 Chiron Spa 741

EP2055189A1

2003-04-09 2009-05-06 Neose Technologies, Inc. Glycopegylation methods and proteins/peptides produced by the methods

GB0316560D0

2003-07-15 2003-08-20 Chiron Srl Vesicle filtration

WO2005012484A2

2003-07-25 2005-02-10 Neose Technologies, Inc. Antibody-toxin conjugates

ES2395022T3

2003-09-19 2013-02-07 Epitopix, Llc Polipéptidos de Campylobacter y sus métodos de uso

SI1961426T1

2003-10-02 2011-10-28 Novartis Ag Kombinirana cepiva proti meningitisu

GB0323709D0

* 2003-10-09 2003-11-12 Health Prot Agency Modified whole cell,cell extract and omv-based vaccines

US20080305992A1

2003-11-24 2008-12-11 Neose Technologies, Inc. Glycopegylated erythropoietin

CA2550927A1

2003-12-23 2005-07-14 Glaxosmithkline Biologicals S.A. A gram negative bacterium with reduced lps level in the outer membrane and use thereof for treating gram negative bacterial infection

GB0408977D0

2004-04-22 2004-05-26 Chiron Srl Immunising against meningococcal serogroup Y using proteins

ES2344114T3

* 2004-05-11 2010-08-18 De Staat Der Nederlanden, Vert. Door De Minister Van Vws Lipooligosacaridos de neisseria meningitidis igtb como adyuvante.

EP1771066A2

2004-07-13 2007-04-11 Neose Technologies, Inc. Branched peg remodeling and glycosylation of glucagon-like peptide-1 glp-1

GB0419408D0

* 2004-09-01 2004-10-06 Chiron Srl 741 chimeric polypeptides

GB0419627D0

* 2004-09-03 2004-10-06 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins

GB0424092D0

2004-10-29 2004-12-01 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins

EP3061461A1

2004-10-29 2016-08-31 ratiopharm GmbH Remodeling and glycopegylation of fibroblast growth factor (fgf)

GB0428381D0

* 2004-12-24 2005-02-02 Isis Innovation Vaccine

EP2514757A3

2005-01-10 2014-03-05 ratiopharm GmbH Glycopegylated granulocyte colony stimulating factor

WO2006079076A2

2005-01-21 2006-07-27 Epitopix, Llc Yersinia spp. polypeptides and methods of use

CN101107007B

2005-01-27 2011-08-17 奥克兰儿童医院及研究中心对脑膜炎奈瑟球菌所致疾病具有广谱保护作用的gna1870囊泡疫苗

EP2386571B1

2005-04-08 2016-06-01 ratiopharm GmbH Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants

MX2007016237A

2005-06-27 2008-03-07 Glaxosmithkline Biolog Sa Composicion inmunogenica.

US20070105755A1

2005-10-26 2007-05-10 Neose Technologies, Inc. One pot desialylation and glycopegylation of therapeutic peptides

US7955817B2

2005-09-02 2011-06-07 Glaxosmithkline Biologicals S.A. Vaccine protection assay

EP2208999B1

* 2005-09-05 2014-08-27 GlaxoSmithKline Biologicals SA Serum bactericidal assay for N. meningitidis specific antisera

US20090048440A1

2005-11-03 2009-02-19 Neose Technologies, Inc. Nucleotide Sugar Purification Using Membranes

GB0524066D0

2005-11-25 2006-01-04 Chiron Srl 741 ii

CA2632434A1

* 2005-12-06 2007-06-14 Universita Degli Studi Di Padova Methods and compositions relating to adhesins as adjuvants

GB0607088D0

2006-04-07 2006-05-17 Glaxosmithkline Biolog Sa Vaccine

TW201350129A

2005-12-22 2013-12-16 Glaxosmithkline Biolog Sa 包含莢膜醣結合物之肺炎鏈球菌免疫原組合物、包含其之疫苗及套組及其用途

CU23549A1

* 2005-12-29 2010-07-20 Ct Ingenieria Genetica Biotech Composiciones farmacéuticas que contienen la proteína nma0939

EA020459B1

2006-03-30 2014-11-28 Глаксосмитклайн Байолоджикалс С.А. Иммуногенная композиция

ES2337309T5

2006-06-12 2013-07-30 Glaxosmithkline Biologicals S.A. Vacuna

EP2049144B8

2006-07-21 2015-02-18 ratiopharm GmbH Glycosylation of peptides via o-linked glycosylation sequences

MX2009002560A

2006-09-07 2009-03-20 Glaxosmithkline Biolog Sa Vacuna.

US20100075375A1

2006-10-03 2010-03-25 Novo Nordisk A/S Methods for the purification of polypeptide conjugates

GB0700136D0

2007-01-04 2007-02-14 Glaxosmithkline Biolog Sa Process for manufacturing vaccines

GB0700562D0

2007-01-11 2007-02-21 Novartis Vaccines & Diagnostic Modified Saccharides

KR20150064246A

2007-04-03 2015-06-10 바이오제너릭스 게엠베하 글리코페길화 ｇ―ｃｓｆ를 이용하는 치료 방법

CN101778859B

2007-06-12 2014-03-26 诺和诺德公司改良的用于生产核苷酸糖的方法

BRPI0813307C1

2007-06-26 2021-05-25 Glaxosmithkline Biologicals Sa composição imunogênica, vacina, e, processo para fabricar a vacina

EP2185576A4

* 2007-08-02 2011-01-12 Childrens Hosp & Res Ct Oak FHBP- AND LPXL1-BASED VESICIUM VACCINES FOR BROADBAND PROTECTION AGAINST NEISSERIA MENINGITIDIS-RELATED DISEASES

EP2185727A2

* 2007-08-02 2010-05-19 GlaxoSmithKline Biologicals SA Novel method

SI2200642T1

2007-10-19 2012-06-29 Novartis Ag Formulacije meningokoknega cepiva

EP2886551A3

* 2008-02-21 2015-09-23 Novartis AG Meningococcal fhbp polypeptides

KR101582841B1

2008-02-27 2016-01-11 노보 노르디스크 에이/에스 콘쥬게이트된 인자 ｖｉｉｉ 분자

RS54190B1

2008-03-03 2015-12-31 Novartis Ag COMPOUNDS AND COMPOSITIONS USED AS TLR FACTORS

MX2010012999A

* 2008-05-30 2012-03-07 U S A As Represented By The Secretary Of The Army On Behalf Of Walter Reed Army Vacuna de vesícula de membrana externa nativa multivalente del meningococo, método para su fabricación y uso.

KR101042541B1

* 2008-07-25 2011-06-17 한국생명공학연구원 외막소체를 생산하는 재조합 ｇ（－） 박테리아 및 이를이용한 다가항원이 실린 외막소체의 제조방법

US20110182981A1

* 2008-08-25 2011-07-28 Peixuan Zhu Gonococcal vaccines

GB0816447D0

* 2008-09-08 2008-10-15 Glaxosmithkline Biolog Sa Vaccine

GB0822634D0

2008-12-11 2009-01-21 Novartis Ag Meningitis vaccines

MX2011006648A

2008-12-17 2011-10-14 Novartis Ag Vacunas meningococales que incluyen receptor de hemoglobina.

CN101759781B

* 2008-12-25 2013-04-03 上海市第六人民医院一种细菌表层黏附蛋白及其用途

ES2616533T3

2008-12-25 2017-06-13 The Chemo-Sero-Therapeutic Research Institute Vacuna recombinante para la rinitis infecciosa aviar y proceso para producir la misma

EP2208787A1

* 2009-01-19 2010-07-21 Université de Liège A recombinant alpha-hemolysin polypeptide of Staphylococcus aureus, having a deletion in the stem domain and heterologous sequences inserted

ES2797504T3

2009-03-24 2020-12-02 Glaxosmithkline Biologicals Sa Proteína de enlace del factor H meningocócico utilizada como adyuvante

RU2549438C2

* 2009-03-24 2015-04-27 Новартис Аг Комбинации, включающие сахарид пневмококка серотипа 14

AU2010227220B2

2009-03-24 2014-11-13 Glaxosmithkline Biologicals S.A. Combinations of meningococcal factor H binding protein and pneumococcal saccharide conjugates

EP2429576A1

* 2009-05-14 2012-03-21 Sanofi Pasteur Vaccin meningocoque a base de lipooligosaccharide (los) et de proteine de neisseria meningitidis

NZ597004A

* 2009-05-14 2013-03-28 Sanofi Pasteur Method for admixing the lipopolysaccharide (lps) of gram-negative bacteria

WO2010130898A2

2009-05-14 2010-11-18 Sanofi Pasteur Vaccin meningocoque a base de lipooligosaccharide (los) provenant de souches modifiees de neisseria meningitidis d'immunotype l6

WO2010134225A1

* 2009-05-20 2010-11-25 国立大学法人鳥取大学部分糖鎖エピトープを用いた、病原性ナイセリア属細菌感染の検出方法およびそれら細菌に対するワクチン

US9517263B2

2009-06-10 2016-12-13 Glaxosmithkline Biologicals Sa Benzonaphthyridine-containing vaccines

GB0913681D0

2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition

CA2772104A1

2009-08-27 2011-03-03 Novartis Ag Hybrid polypeptides including meningococcal fhbp sequences

EP2470205A1

2009-08-27 2012-07-04 Novartis AG Adjuvant comprising aluminium, oligonucleotide and polycation

US9201072B2

2009-09-01 2015-12-01 Aeon Medix Inc. Gut flora-derived extracellular vesicles, and method for searching for a disease model, vaccine, and candidate drug and for diagnosis using the same

WO2011027956A2

2009-09-04 2011-03-10 주식회사이언메딕스 그람 양성 박테리아에서 유래한 세포밖 소포체 및 이를 이용한 질병 모델

JO3257B1

2009-09-02 2018-09-16 Novartis Ag مركبات وتركيبات كمعدلات لفاعلية tlr

MX2012002723A

2009-09-02 2012-04-11 Novartis Ag Composiciones inmunogenicas que incluyen moduladores de la actividad de receptores tipo toll.

GB0917002D0

* 2009-09-28 2009-11-11 Novartis Vaccines Inst For Global Health Srl Improved shigella blebs

GB0917003D0

2009-09-28 2009-11-11 Novartis Vaccines Inst For Global Health Srl Purification of bacterial vesicles

AU2010302344A1

2009-09-30 2012-04-26 Novartis Ag Expression of meningococcal fhbp polypeptides

US20130022633A1

2009-10-27 2013-01-24 University Of Florence MENINGOCOCCAL fHBP POLYPEPTIDES

WO2011057148A1

2009-11-05 2011-05-12 Irm Llc Compounds and compositions as tlr-7 activity modulators

CA2779839A1

* 2009-11-06 2011-05-12 Children's Hospital & Research Center At Oakland T-cell stimulating protein b and methods of use

JP5814933B2

2009-12-15 2015-11-17 ノバルティスアーゲー免疫増強化合物の均質な懸濁物およびその使用

WO2011110634A1

* 2010-03-10 2011-09-15 Glaxosmithkline Biologicals S.A. Vaccine composition

JP2013522177A

* 2010-03-11 2013-06-13 グラクソスミスクラインバイオロジカルズソシエテアノニムグラム陰性細菌性、例えば髄膜炎菌性の感染または疾患に対する免疫原性組成物またはワクチン

CN102802662A

2010-03-18 2012-11-28 诺华有限公司用于脑膜炎球菌血清组b的含佐剂疫苗

WO2011119759A1

2010-03-23 2011-09-29 Irm Llc Compounds (cystein based lipopeptides) and compositions as tlr2 agonists used for treating infections, inflammations, respiratory diseases etc.

MX2012010793A

* 2010-03-29 2013-05-09 Univ Southern California Composiciones y metodos para la eliminacion de biopeliculas.

AU2013202310C1

* 2010-03-29 2017-01-05 Nationwide Children's Hospital, Inc. Compositions and methods for the removal of biofilms

EP2585106A1

2010-06-25 2013-05-01 Novartis AG Combinations of meningococcal factor h binding proteins

EP2613797B1

2010-09-09 2015-11-04 University Of Southern California Compositions and methods for the removal of biofilms

GB201015132D0

2010-09-10 2010-10-27 Univ Bristol Vaccine composition

ES2759484T3

2010-09-10 2020-05-11 Glaxosmithkline Biologicals Sa Meningococo que sobreexpresa NadA y/o NHBA y vesículas de la membrana externa derivadas del mismo

WO2012041899A1

* 2010-09-28 2012-04-05 Xbrane Bioscience Ab Fusion protein for secretory protein expression

WO2012054879A1

* 2010-10-22 2012-04-26 Duke University Compositions and methods for the treatment of septic arthritis, osteomyelitis, and bacteremia

EP2707009A1

2011-05-12 2014-03-19 Novartis AG Antipyretics to enhance tolerability of vesicle-based vaccines

US9272006B2

2011-07-07 2016-03-01 De Staat Der Nederlanden, Vert. Door De Minister Van Vws Ministerie Van Volksgezondheid, Welzijn En Sport Process for detergent-free production of outer membrane vesicles of a gram-negative bacterium

AU2011384634A1

2011-12-29 2014-06-19 Novartis Ag Adjuvanted combinations of meningococcal factor H binding proteins

WO2013113917A1

2012-02-02 2013-08-08 Novartis Ag Promoters for increased protein expression in meningococcus

JP5698693B2

* 2012-03-13 2015-04-08 グラクソスミスクラインバイオロジカルズソシエテアノニム髄膜炎菌特異的抗血清に対する血清殺菌アッセイ

RU2644340C2

2012-06-14 2018-02-08 Новартис Аг Вакцины для менингококка серогруппы х

JP6324961B2

2012-09-06 2018-05-16 ノバルティスアーゲー血清群ｂ髄膜炎菌とｄ／ｔ／ｐとの組み合わせワクチン

EP2897635A1

2012-09-18 2015-07-29 Novartis AG Outer membrane vesicles

EP2953620A1

2013-02-07 2015-12-16 GlaxoSmithKline Biologicals SA Pharmaceutical compositions comprising vesicles

WO2014138290A1

* 2013-03-05 2014-09-12 Trudeau Institute, Inc. Compositions and methods for treating bacterial infections

US11274144B2

2013-06-13 2022-03-15 Research Institute At Nationwide Children's Hospital Compositions and methods for the removal of biofilms

US9745366B2

2013-09-23 2017-08-29 University Of Southern California Compositions and methods for the prevention of microbial infections

US11248040B2

2013-09-26 2022-02-15 Trellis Bioscience, Llc Binding moieties for biofilm remediation

US10233234B2

2014-01-13 2019-03-19 Trellis Bioscience, Llc Binding moieties for biofilm remediation

US10392424B2

2014-02-28 2019-08-27 Glaxosmithkline Biologicals Sa Modified meningococcal fHbp polypeptides

EP3229835A1

* 2014-12-09 2017-10-18 Sanofi Pasteur Compositions comprising n. meningitidis proteins

EP3838918B1

2015-05-18 2022-08-31 BiOMVis Srl Immunogenic compositions containing bacterial outer membrane vesicles and therapeutic uses thereof

AU2016303688B2

2015-07-31 2023-06-15 Research Institute At Nationwide Children's Hospital Peptides and antibodies for the removal of biofilms

EP3365027B1

2015-10-14 2022-03-30 Research Institute at Nationwide Children's Hospital Hu specific antibodies and their use in inhibiting biofilm

KR101825439B1

* 2016-04-15 2018-02-05 배재대학교 산학협력단 염산 처리에 의한 그람양성 박테리아 고스트의 제조 방법

US11564982B2

2017-01-04 2023-01-31 Research Institute At Nationwide Children's Hospital DNABII vaccines and antibodies with enhanced activity

AU2018206560B2

2017-01-04 2025-01-30 Research Institute At Nationwide Children's Hospital Antibody fragments for the treatment of biofilm-related disorders

WO2018170178A1

2017-03-15 2018-09-20 Research Institute At Nationwide Children's Hospital Composition and methods for disruption of bacterial biofilms without accompanying inflammation

EP3607967A1

2018-08-09 2020-02-12 GlaxoSmithKline Biologicals S.A. Modified meningococcal fhbp polypeptides

WO2020094580A1

* 2018-11-06 2020-05-14 Glaxosmithkline Biologicals Sa Immunogenic compositions

WO2020168146A1

* 2019-02-14 2020-08-20 University Of Florida Research Foundation, Inc. Honeybee commensal snodgrassella alvi vaccine against pathogenic neisseriaceae

FR3099160B1

* 2019-07-23 2022-05-06 Univ Grenoble Alpes Anticorps dirigé contre la protéine oprf depseudomonas aeruginosa, son utilisation en tant que médicament et composition pharmaceutique le contenant

EP3975368A1

2020-09-25 2022-03-30 Wobben Properties GmbH Unterbrechungsfreie stromversorgung bei windenergieanlagen

WO2023097652A1

* 2021-12-03 2023-06-08 National Center For Nanoscience And Technology An engineered cell and application thereof

GB202203250D0

2022-03-09 2022-04-20 Glaxosmithkline Biologicals Sa Immunogenic compositions

* Cited by examiner, † Cited by third party, ‡ Family to family citation